2-heteroaryl aminoquinazolinone derivative
Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein X 1 represents CR 1 or N, X 2 represents CR 2 or N, X 3 represents CR 3 or N, X 4 represents CR 4 or N, Y represents optionally substituted C 1-6 alkyl, an optionally substituted C 3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C 6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R 1 , R 2 , R 3 , and R 4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, or the like.
1. A compound selected from:
4-oxo-3-phenyl-2-(pyridin-3-ylamino)-3,4-dihydroquinazoline-6-carbonitrile,
6-fluoro-3-phenyl-2-(pyridin-3-ylamino)quinazolin-4(3H)-one,
6-fluoro-2-((5-fluoropyridin-3-yl)amino)-3-phenylquinazolin-4(3H)-one,
4-oxo-2-(pyridin-3-ylamino)-3-(o-tolyl)-3,4-dihydroquinazoline-6-carbonitrile and
2-((5-fluoropyridin-3-yl)amino)-4-oxo-3-(o-tolyl)-3,4-dihydroquinazoline-6-carbonitrile,
or a pharmaceutically acceptable salt thereof.
2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , which is
4-oxo-3-phenyl-2-(pyridin-3-ylamino)-3,4-dihydroquinazoline-6-carbonitrile, or a pharmaceutically acceptable salt thereof.
3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , which is
6-fluoro-3-phenyl-2-(pyridin-3-ylamino)quinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
4. The compound or pharmaceutically acceptable salt thereof according to claim 1 , which is
6-fluoro-2-((5-fluoropyridin-3-yl)amino)-3-phenylquinazolin-4(3H)-one, or a pharmaceutically acceptable salt thereof.
5. The compound or pharmaceutically acceptable salt thereof according to claim 1 , which is
4-oxo-2-(pyridin-3-ylamino)-3-(o-tolyl)-3,4-dihydroquinazoline-6-carbonitrile, or a pharmaceutically acceptable salt thereof.
6. The compound or pharmaceutically acceptable salt thereof according to claim 1 , which is
2-((5-fluoropyridin-3-yl)amino)-4-oxo-3-(o-tolyl)-3,4-dihydroquinazoline-6-carbonitrile, or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1 to suppress neural circuit hyperexcitation.
8. A pharmaceutical composition, comprising:
an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 to suppress neural circuit hyperexcitation; and
at least one pharmaceutically acceptable excipient.
9. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 2 to suppress neural circuit hyperexcitation.
10. A pharmaceutical composition, comprising:
an of amount of the compound or pharmaceutically acceptable salt thereof of claim 2 to suppress neural circuit hyperexcitation; and
at least one pharmaceutically acceptable excipient.
11. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 3 to suppress neural circuit hyperexcitation.
12. A pharmaceutical composition, comprising:
an effective amount of the compound or a pharmaceutically acceptable salt thereof of claim 3 to suppress neural circuit hyperexcitation; and
at least one pharmaceutically acceptable excipient.
13. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 4 to suppress neural circuit hyperexcitation.
14. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 4 to suppress neural circuit hyperexcitation; and
at least one pharmaceutically acceptable excipient.
15. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 5 to suppress neural circuit hyperexcitation.
16. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 5 to suppress neural circuit hyperexcitation; and
at least one pharmaceutically acceptable excipient.
17. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 6 to suppress neural circuit hyperexcitation.
18. A pharmaceutical composition, comprising:
an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 6 to suppress neural circuit hyperexcitation; and
at least one pharmaceutically acceptable excipient.